Cheaper Wegovy, 23andMe shutters, and RFK Jr. cuts FDA jobs: Pharma news roundup
Novo Nordisk is expanding its cash-only savings program offering its blockbuster weight-loss drug Wegovy for $499 a month at all U.S. pharmacies. 23andMe has filed for Chapter 11 bankruptcy protection with CEO Anne Wojcicki stepping down to help with a sale. And the U.S. Department of Health and Human Services (HHS)…Read more...
Novo Nordisk is expanding its cash-only savings program offering its blockbuster weight-loss drug Wegovy for $499 a month at all U.S. pharmacies. 23andMe has filed for Chapter 11 bankruptcy protection with CEO Anne Wojcicki stepping down to help with a sale. And the U.S. Department of Health and Human Services (HHS)…
